Daraxonrasib Shows 38% Response in KRAS G12C Lung Cancer Trial

A study published this week in the New England Journal of Medicine indicates that daraxonrasib, a RAS‑protein inhibitor already cleared by the U.S. Food and Drug Administration for use in metastatic pancreatic cancer, may also be effective against certain forms of lung cancer. The multicenter trial, which enrolled 312 patients with advanced non‑small‑cell lung carcinoma harboring KRAS G12C mutations, reported an overall response rate of 38 % and a median progression‑free survival of 7.4 months, figures that compare favorably with existing targeted therapies. The authors, a consortium of academic oncologists and researchers from the drug’s manufacturer, emphasized that the findings are based on a pre‑planned subgroup analysis and that larger, phase‑III studies are needed to confirm efficacy and safety.

Daraxonrasib belongs to a newer generation of drugs that directly target mutant RAS proteins, a class of intracellular signalling molecules long considered “undruggable.” The FDA granted the drug accelerated approval in 2023 after a pivotal trial demonstrated a survival benefit in patients with KRAS‑mutated pancreatic adenocarcinoma, a disease with few effective options. Its mechanism—binding covalently to the mutant cysteine residue in KRAS G12C—halts downstream signalling that drives tumor growth. While the pancreatic indication has been the primary focus of regulatory review, the drug’s molecular specificity suggests potential activity across multiple tumour types that share the same KRAS mutation, a hypothesis now supported by the NEJM data.

The publication in the New England Journal of Medicine carries particular weight because the journal is widely regarded as one of the most influential peer‑reviewed outlets in clinical medicine. Its 2024 impact factor of 78.5 places it second among 168 journals in the “Medicine, General & Internal” category, reflecting rigorous editorial standards and a high citation rate. Consequently, the study’s appearance in NEJM is likely to accelerate interest from both the oncology community and investors, prompting discussions about expanding the drug’s label and initiating additional trials in other KRAS‑driven cancers such as colorectal and melanoma.

Industry reaction has been cautiously optimistic. The drug’s developer, Oncogene Therapeutics, released a statement noting that the lung‑cancer results “reinforce the broader therapeutic potential of daraxonrasib” and that the company will engage with the FDA to explore an amendment to the drug’s indication. Oncology societies have called for peer‑reviewed, randomized controlled trials to validate the findings and to assess the drug’s safety profile in a larger lung‑cancer cohort, particularly regarding known adverse events such as liver enzyme elevations and gastrointestinal toxicity. Meanwhile, health‑technology assessment bodies in Europe and Asia are monitoring the data as they prepare reimbursement frameworks for targeted therapies that often carry high price tags.

The implications of the study extend beyond the immediate clinical arena. Taiwan’s biomedical sector, which has become a hub for contract research, clinical‑trial services, and precision‑medicine technologies, could play a role in subsequent phase‑III investigations. Taiwanese companies specialize in high‑throughput genomic sequencing and bioinformatics platforms that are essential for identifying patients with KRAS G12C mutations, a prerequisite for enrolling in targeted‑therapy trials. Moreover, the island’s robust semiconductor manufacturing base underpins many diagnostic devices used in oncology, from imaging equipment to liquid‑biopsy platforms. Should daraxonrasib receive broader regulatory approval, the demand for such technologies and associated services is likely to rise, offering opportunities for Taiwanese firms to integrate further into the global oncology drug development pipeline.